[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"geriatric-oncology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:geriatric-oncology":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,73,116,158],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100630227","trtrm-acttop--guided-dosing-strategy-in-older-patients-with-cancer-100630227",false,"NCT07484932","TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer","Clinical Utility of the Treatment-related Toxicity Risk Model (TRTRM\u002F ACTTOP) in Older Patients With Cancer: a Randomised Controlled Trial","Inclusion Criteria:\n\n1. Aged 65 or above\n2. A diagnosis of lung cancer, gastrointestinal cancer, breast cancer, prostate cancer, and uterine cancer with histological confirmation or radiological diagnosis\\*\\*\n3. Seen by the oncologist and scheduled to receive a new systemic anti-cancer treatment, including chemotherapy, targeted therapy, and immunotherapy, in either radical or first\u002Fsecond-line palliative intent. The planned treatment regimen is expected to last for at least 3 months.\n4. ECOG performance status of 0-2\n5. Agreement for treatment according to the TRTRM (ACTTOP) -risk strategy if in the TRTRM (ACTTOP) -informed care group\n6. Fluent in English or Chinese\n7. Valid consent obtained \\*\\* Only these five types of cancer are included to reduce the heterogeneity of the patients, as they are the top 5 cancers in Hong Kong.\n\nExclusion Criteria:\n\n1. Planned for radiotherapy alone\n2. Planned for systemic treatment concomitant with radiotherapy\n3. Scheduled to have hormonal therapy alone e.g. tamoxifen, aromatase inhibitors, luteinizing hormone-releasing hormone agonist (LHRHa)\n4. Planned for surgery within 3 months\n5. Dementia or patient mentally not fit for consent","ALL","65 Years",{"count":19,"type":20},400,"ESTIMATED","INTERVENTIONAL",[23],"NA","Older adults receiving systemic cancer treatments are at increased risk of developing severe treatment-related toxicities (TRT). Existing prediction tools such as CARG and CRASH have limited applicability in Chinese populations and do not fully address toxicities associated with newer therapies, including immunotherapy and targeted agents. The Treatment-related Toxicity Risk Model (TRTRM) was recently developed and validated in Hong Kong using data from 700 older cancer patients and has demonstrated better predictive accuracy and clinical relevance compared with existing tools.\n\nThis multi-center, open-label, randomized controlled trial aims to evaluate the clinical utility of the TRTRM by guiding treatment dose intensity and monitoring strategies. Participants aged 65 years or older who are starting a new systemic anti-cancer treatment will be randomized in a 1:1 ratio to receive either usual care or TRTRM-informed care. In the intervention arm, patients identified as having intermediate or high risk of toxicity will receive a \"start-low, go-slow\" dosing strategy with close monitoring, while low-risk patients will receive standard dosing.\n\nThe primary outcome is the incidence of grade 3 or higher treatment-related toxicities within the first two months of treatment initiation. Secondary outcomes include emergency visits, unplanned hospitalizations, premature treatment termination, early mortality, quality of life, and overall survival.",[26,27],"Cancer (Solid Tumors)","Geriatric Oncology",[29,30,31,32,33],"toxicities","prediction model","ACTTOP","Older patients","geriatrics","RECRUITING","2026-05-16",{"date":37,"type":38},"2026-05-20","ACTUAL",{"date":40,"type":38},"2026-05-04",{"date":42,"type":20},"2030-07-31",{"name":44,"class":45},"The University of Hong Kong","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100550135","preparation-for-medical-and-surgical-procedures-in-oncogeriatry-100550135","NCT06443138","Preparation for Medical and Surgical Procedures in Oncogeriatry.","Preparation for Medical and Surgical Procedures in Oncogeriatry. Pilote Study PRIMECHO","PRIMECHO","Inclusion Criteria:\n\n* Patient aged 70 or over\n* Cancer patient with planned surgery,\n* Mini Mental State Examination score greater than or equal to 24 (performed in advance by the geriatrician),\n* Patient affiliated to or benefiting from a social security insurance\n* Signed free and informed consent.\n\nExclusion Criteria:\n\n* Inability to walk or perform unsupervised exercises.\n* Vulnerable people","70 Years",{"count":57,"type":20},20,[23],"Surgical management is one of the most frequently used interventions in the treatment of many cancers, but it can be associated with a high risk of postoperative complications.\n\nThe maintenance and optimization of functional abilities before, during and after treatment are major for elderly cancer patients, as it is now well established that there is a link between the level of functional capacity and the occurrence of these complications.\n\nThe scientific literature shows that the benefits of pre- and post-operative training programs, but these benefits only apply to a fraction of the patients adhering to the programs. The modalities of intervention (training load, follow-up, etc.) as well as patient involvement in these programs are major issues that need to be addressed to optimize their benefits.\n\nIndividualizing pre-habilitation, on the basis of the management of the training load, and therefore objective fatigue, would enable better patient adherence to the program, and optimize its benefits.\n\nIn this context, the PRIMECHO project aims to individualize pre-habilitation in order to improve functional of patients in the pre-habilitation or accelerated recovery after surgery phase. The aim is for the patient to be in optimum physical condition at the time of the intervention or treatment.",[27],[62,63],"ederly","cancer","2026-03-17",{"date":66,"type":38},"2026-03-19",{"date":68,"type":38},"2024-11-06",{"date":70,"type":20},"2027-11-10",{"name":72,"class":45},"Centre Hospitalier Universitaire de Nice",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100493872","the-save-project-sarcopenia-and-vertigo-in-aging-patients-with-colorectal-cancer-100493872","NCT05710809","The SaVe Project-Sarcopenia and Vertigo in Aging Patients With Colorectal Cancer","SaVe","Inclusion Criteria:\n\n* Meet the criteria of the oncological departments of receiving neoadjuvant, adjuvant or first line palliative chemotherapy for colorectal cancer\n* ≥65 years of age at the time of signing the informed consent form\n* Able to speak and read Danish, and to provide a signed informed consent form\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2\n\nExclusion Criteria:\n\n* Chemotherapy treatment within two years and sequelae of neuropathy, or symptoms of dizziness or vertigo, or balance disturbance\n* Severe physical disability that hinders physical exercise\n* Dementia, psychotic disorders, or other cognitive diseases or conditions that hinder participation in a clinical exercise-based trial\n* Inability to sign informed content\n* Patients who have had a consultation in the geriatric outpatient clinic within the past six months",{"count":81,"type":20},150,[23],"The goal of this clinical trial is to learn about the cause of dizziness and decline in walking ability in in older adults ≥65 years during chemotherapy treatment for colorectal cancer. Another goal is to investigate if a comprehensive geriatric assessment and three months' specialized physical group-based exercise three times\u002Fweek can counteract muscle weakness, vertigo, instability, impaired walking balance, and neuropathy",[85,86,87,88,27,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105],"Colorectal Cancer","Oncologic Complications","Comprehensive Geriatric Assessment","Vestibular Rehabilitation","Sarcopenia","Vertigo","Cancer","Rehabilitation","Exercise","Geriatric","Elderly","Frail","Older Adults","Chemotherapy","Chemotherapy-induced Peripheral Neuropathy","Resistance Training","Balance Training","Postural Stability","Pragmatic Trial","Personal Medicine","Individualised","2025-04-02",{"date":108,"type":38},"2025-04-06",{"date":110,"type":38},"2023-02-20",{"date":112,"type":20},"2027-09",{"name":114,"class":45},"Rigshospitalet, Denmark",2,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":124,"sex":16,"minAge":125,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":129,"conditions":130,"keywords":141,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":157},"100466092","comprehensive-outcomes-for-after-cancer-health-100466092","NCT05349227","Comprehensive Outcomes for After Cancer Health","Comprehensive Outcomes for After Cancer Health (COACH): the Feasibility and Impact of an MHealth Augmented Coaching Program for Self-Management in Cancer Survivors","COACH","Inclusion Criteria:\n\n1. Have primary diagnosis of cancer;\n2. Are within 1 year of completion of primary therapy OR have a diagnosis of metastatic cancer\n\n   1. For the purpose of this study, primary therapy is defined as treatment of curative intent, first-line or later, from which the individual is advancing to active surveillance or follow-up with or without maintenance therapy\n   2. For individuals with metastatic cancer, individuals may be included provided they completed primary therapy for a de novo diagnosis of metastatic disease within the last year, are within one year of completion of initial therapy for their primary cancer diagnosis for which disease progression has occurred, or who are within one year of receiving treatment for metastatic disease (including individuals currently receiving treatment).\n3. Are aged 18 years and older;\n4. Can read and consent to participate in the trial;\n5. Can read and speak English;\n6. Can complete study follow-up at pre-specified intervals;\n7. Have access to mobile technology (e.g. a smart phone or tablet) that would allow engagement in digital health coaching for the collection of PROs and wearable data.\n\nExclusion Criteria:\n\n1. Have a cognitive impairment (as assessed by their provider) that would prohibit the individual from engaging with the digital health coaching program or complete study assessments;\n2. Have a neurologic, musculoskeletal, or other comorbid condition that would impede their ability to engage in physical activity (as assessed by their provider)\n3. Have a life expectancy of \\<6 months, and\u002For\n4. Are on active treatment for relapsed disease. a. Individuals with disease progression or relapse which occurs following their consent to participate will be given the option to continue on study if they wish to do so. Data from individuals experiencing disease progression or relapse will be grouped for sub-analysis to explore if and how relapse impacts study outcomes.\n\nHealthy Volunteers must:\n\n1. Be adults aged 18 years or older or the age of majority in their state of residence, whichever is older.\n2. Must reside in the same dwelling as the patient participant\n3. Can read and consent to participate in the trial;\n4. Can read and speak English;\n5. Can complete study follow-up at pre-specified intervals;",true,"18 Years",{"count":127,"type":20},625,[23],"This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to participate in a randomized wait-list control study. Those in the intervention group will receive 6 months of digital coaching up front followed by 6 months of ongoing monitoring via patient reported and clinical outcomes, as well as wearable data. Those in the control group will be monitored via patient reported and clinical outcomes as well as wearable data for the first 6 months followed by 6 months of digital health coaching. Both groups will collect fecal microbiome samples at enrollment and month 6. The study aims to explore if and how digital health coaching may be used to enhance outcomes for individuals following completion of primary cancer therapy.",[131,132,133,134,135,136,137,138,27,139,140],"Ovarian Cancer","Breast Cancer","Lung Cancer","Gastric Cancer","Survivorship","Endometrial Cancer","Head and Neck Cancers","Prostate Cancers","Metastatic Breast Cancer","Metastatic Cancer",[142,143,144,145,146],"Patient Reported Outcome Measures","Physical Activity","Digital Coaching","Microbiome","Wearables","2024-12-06",{"date":149,"type":38},"2024-12-11",{"date":151,"type":38},"2022-06-23",{"date":153,"type":20},"2027-05",{"name":155,"class":156},"Pack Health","INDUSTRY",7,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":165,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":46},"100558612","the-gos-frail-geriatric-oncology-supportive-care-for-frail-older-adults-with-cancer-study-100558612","NCT06553378","The GOS-Frail (Geriatric Oncology Supportive Care for Frail Older Adults With Cancer) Study","GOS-Frail","Inclusion criteria\n\n1. Age ≥ 65\n2. Diagnosis of solid organ cancer\n3. Plan for curative-intent chemotherapy and\u002For radiotherapy\n4. Clinical Frailty Scale (CFS) score ≥ 4,\n\nExclusion criteria: Evaluation by Geriatric or Palliative Medicine in the previous 6 months.","21 Years",{"count":167,"type":20},154,[23],"Background Cancer is more prevalent in older adults, but most cancer treatment trials have mainly involved young and healthy subjects. Among geriatric syndromes, frailty is a significant risk factor for negative outcomes such as treatment delays, discontinuation, and treatment-related side effects, as well as functional decline and poor survival. Research has shown that geriatric assessment with appropriate intervention can improve these outcomes, although the impact may be influenced by the inclusion of patients receiving palliative-intent treatment. Supportive care focuses on symptom assessment and treatment to enhance treatment tolerance and quality of life. To date, there have been no studies examining the combined benefits of geriatric oncology and supportive care clinics. We conducted a pilot study called Geriatric Oncology Supportive Clinic for Elderly (GOSPEL), which demonstrated an improved quality of life for older adults with curable cancer. Based on these results, we developed an enhanced care model.\n\nAim The study GOS-Frail aims to assess the effect of an integrated Geriatric Oncology Supportive Clinic on the quality of life of older adults with cancer receiving curative-intent chemotherapy and\u002For radiotherapy at 1 month.\n\nMethods The GOS-Frail study is a multi-centre, open-label, parallel-arm, randomized controlled trial conducted in the specialist outpatient clinics of two university-affiliated tertiary care hospitals. 154 adults aged 65 and above, diagnosed with solid organ cancer and planned for curative-intent chemotherapy and\u002For radiotherapy, and with a clinical frailty scale score of 4 and above, will be recruited. Subjects will be randomized to either attend a geriatric oncology supportive clinic or receive frailty education material. Quality of life questionnaires will be administered at baseline, 2 weeks, and 1, 3, 6, and 12 months from treatment initiation.\n\nHypothesis:\n\nThe GOS-Frail study investigates on the role of a synergistic geriatric oncology and supportive model of care in improving quality of life in older adults undergoing curative-intent cancer treatment.",[27,171,172],"Supportive Care","Quality of Life",[27,171,172],"NOT_YET_RECRUITING","2024-08-13",{"date":177,"type":38},"2024-08-14",{"date":179,"type":20},"2024-09-01",{"date":181,"type":20},"2027-08-31",{"name":183,"class":45},"Tan Tock Seng Hospital"]